This Quality Improvement (QI) program aims to optimise pharmacological and non-pharmacological management of lipid abnormalities in patients with atherogenic dyslipidaemia, to achieve a reduction in cardiovascular disease risk in patients.
This module seeks to educate GPs and others working in the primary care space about how genomic testing can improve patient outcomes, the appropriate referral pathways, issues surrounding notifying family when genomic testing reveals a hereditary condition, and legal matters such as privacy and impact on insurance.
Staying abreast of all of the latest medical guidelines can be a tough gig for many busy primary care professionals. Dr Simon Cowap speaks on guiding his way through all of the guides available, and extracts his most important findings from the latest heart failure guidelines release.
